IR1 Insulin resistance in muscle (ICDM & AASD) | Thursday, 7 November 10:20~11:50 / Emerald hall B Chair: Kap-Bum Huh |
Young-Gyu Ko |
IR1-1 MG53 is a therapeutic target for type 2 diabetes | ||
Nobuharu Fujii Tokyo Metropolitan University, Japan |
IR1-2 MIF is a myokine that regulates glucose transport induced by insulin and AICAR in skeletal muscle | ||
Gary Sweeney York University, Canada |
IR1-3 Mechanisms regulating insulin sensitivity in skeletal muscle |
IR2 Understanding lipid metabolism to reduce insulin resistance (AASD) |
Thursday, 7 November 16:00~17:30 / Emerald hall B Chair: Yong-Wook Cho |
Jae Woo Kim Yonsei University, Korea |
IR2-1 Dexras1, a new link between glucocorticoid and insulin/IGF-1 signaling in adipocytes | ||
Bao-Liang Song Shanghai Institutes, China |
IR2-2 Inhibition of lipid biosynthesis increases energy expenditure and insulin sensitivity | ||
Toshimasa Yamauchi University of Tokyo, Japan |
IR2-3 Pathophysiological roles of AdipoRs in the regulation of insulin sensitivity |
IR3 Autophagy in insulin resistance (ICDM) | Friday, 8 November 09:00~10:30 / Emerald hall B Chair: Sung Hee Ihm |
IR4 Adipose tissue inflammation (AASD) | Friday, 8 November 15:00~16:30 / Emerald hall B Chair: Kyoil Suh |
IR5 Adipokines and hepatokines (ICDM) | Saturday, 9 November 09:00~10:30 / Emerald hall B Chair: Kyong Soo Park |
Matthias Blüher University of Leipzig, Germany |
IR5-1 Adipose tissue dysfunction contributes to insulin resistance in obesity | ||
Jae Bum Kim Seoul National University, Korea |
IR5-2 Multiple roles of adipocytokines in metabolic complications | ||
Kyung Mook Choi Korea University, Korea |
IR5-3 The role of novel adipokines and hepatokines in metabolic and vascular disease |